Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company expects strong organic growth in sales, EBITDA in 2022
The transaction is expected to close in the first quarter of 2022
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Subscribe To Our Newsletter & Stay Updated
